Everest Medicines (01952) has announced that Velsipity (etrasimod arginine tablets) and Xerava (eravacycline hydrochloride for injection) have successfully passed the national medical insurance negotiation and been included for the first time in the new edition of the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2026).
This reimbursement approval is expected to further enhance the accessibility and affordability of both Velsipity and Xerava, giving more patients the opportunity to benefit from innovative treatments. The new version of the national reimbursement drug list will officially take effect on January 1, 2027.
Meanwhile, Nefecon (budesonide enteric-coated capsules) will continue to remain on the national reimbursement drug list.
Velsipity (etrasimod arginine tablets) is China's first and only (as of November 2026) approved sphingosine-1-phosphate (S1P) receptor modulator for the treatment of ulcerative colitis (UC), administered as a once-daily oral dose. Its inclusion in the national reimbursement drug list adds a first-line guideline-recommended oral treatment option for ulcerative colitis.
Xerava (eravacycline hydrochloride for injection) is the world's first and only (as of November 2026) fully synthetic fluorocycline antibacterial agent, indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. It features a broad antibacterial spectrum, strong antibacterial activity, confirmed clinical efficacy, and a favorable safety profile.
Comments